Quick Answer
Protagonist Therapeutics, Inc reported Net Income of -$130.15 million for fiscal year 2025.
Protagonist Therapeutics, Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$130.15M -147.3% |
$275.19M +448.5% |
-$78.95M +38.0% |
-$127.39M -1.5% |
-$125.55M -89.8% |
-$66.15M +14.3% |
| Diluted EPS | -$2.05 -148.5% |
$4.23 +404.3% |
-$1.39 +46.5% |
-$2.60 +4.1% |
-$2.71 -41.1% |
-$1.92 |
| Total Assets | $668.19M -10.3% |
$744.73M +108.1% |
$357.95M +44.4% |
$247.93M -28.7% |
$347.69M +7.2% |
$324.47M +109.4% |
| Cash and Equivalents | $128.39M +32.0% |
$97.25M -47.9% |
$186.73M +48.5% |
$125.74M +1.7% |
$123.67M +5.4% |
$117.36M +255.6% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $614.71M -9.0% |
$675.29M +100.6% |
$336.68M +56.2% |
$215.61M -28.1% |
$300.02M +7.3% |
$279.61M +249.7% |
| R&D Expense | $159.29M +15.3% |
$138.13M +15.0% |
$120.16M -4.8% |
$126.22M +0.2% |
$126.01M +69.1% |
$74.51M +14.6% |
| Operating Income | -$158.13M -162.5% |
$252.84M +370.0% |
-$93.65M +28.7% |
-$131.37M -4.4% |
-$125.84M -95.1% |
-$64.52M +19.9% |
| Shares Outstanding | 62.58M +2.5% |
61.04M +5.8% |
57.71M +17.0% |
49.34M +3.1% |
47.84M +9.4% |
43.75M +60.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2017 | $8.78M | — | — |
| Net Income | September 30, 2025 | -$39.34M | -18.5% | -13.1% |
| Diluted EPS | September 30, 2025 | -$0.62 | -14.8% | -12.7% |
| Total Assets | September 30, 2025 | $701.69M | +16.2% | -2.3% |
| Cash and Equivalents | September 30, 2025 | $113.71M | -13.3% | -32.5% |
| Long-Term Debt | March 31, 2020 | $9.83M | — | +0.4% |
| Stockholders Equity | September 30, 2025 | $645.44M | +21.3% | -3.4% |
| R&D Expense | September 30, 2025 | $40.00M | +11.2% | +8.0% |
| Operating Income | September 30, 2025 | -$46.42M | -12.0% | -10.4% |
| Shares Outstanding | September 30, 2025 | 62.45M | +4.9% | +0.5% |
- Protagonist Therapeutics, Inc reported Net Income of -$130.15 million for fiscal year 2025.
- Protagonist Therapeutics, Inc showed a decrease of -147.3% in Net Income compared to the prior fiscal year.
- Protagonist Therapeutics, Inc reported Diluted EPS of $2.05 per share (loss) for fiscal year 2025.
- Protagonist Therapeutics, Inc showed a decrease of -148.5% in Diluted EPS compared to the prior fiscal year.
- Protagonist Therapeutics, Inc reported Total Assets of $668.19 million for fiscal year 2025.
- Protagonist Therapeutics, Inc showed a decrease of -10.3% in Total Assets compared to the prior fiscal year.
- Protagonist Therapeutics, Inc reported Cash and Equivalents of $128.39 million for fiscal year 2025.
- Protagonist Therapeutics, Inc showed an increase of +32.0% in Cash and Equivalents compared to the prior fiscal year.
- Protagonist Therapeutics, Inc reported Long-Term Debt of $9.79 million for fiscal year 2019.
- Protagonist Therapeutics, Inc reported Stockholders Equity of $614.71 million for fiscal year 2025.
- Protagonist Therapeutics, Inc showed a decrease of -9.0% in Stockholders Equity compared to the prior fiscal year.
- Protagonist Therapeutics, Inc reported R&D Expense of $159.29 million for fiscal year 2025.
- Protagonist Therapeutics, Inc showed an increase of +15.3% in R&D Expense compared to the prior fiscal year.
- Protagonist Therapeutics, Inc reported Operating Income of -$158.13 million for fiscal year 2025.
- Protagonist Therapeutics, Inc showed a decrease of -162.5% in Operating Income compared to the prior fiscal year.
- Protagonist Therapeutics, Inc reported Shares Outstanding of 62.58 million shares for fiscal year 2025.
- Protagonist Therapeutics, Inc showed an increase of +2.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: